Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Translational studies for target-based drugs.

Kazuto Nishio1, Tokuzo Arao, Tatsu Shimoyama

  • 1Shien Lab, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, 104-0045, Tokyo, Japan. knishio@gam2.res.ncc.go.jp

Cancer Chemotherapy and Pharmacology
|November 8, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intratumoral heterogeneity of intermediate CLDN18.2 expression in gastric cancer.

International journal of clinical oncology·2026
Same author

Changes in plasma cfDNA ERBB2 copy number reflect prognosis in HER2-positive gastric cancer: a correlative analysis of the KSCC-TROX A2 study.

International journal of clinical oncology·2026
Same author

Clinical Prediction of Glycolysis-Driven Molecular Subclass of Hepatocellular Carcinoma without Transcriptomic Profiling.

Liver cancer·2026
Same author

Muscle loss and pentraxin-3 as predictors of immunotherapy outcomes in non-small cell lung cancer: a prospective study.

Scientific reports·2026
Same author

Mutation-Specific Response to Ramucirumab in <i>EGFR-</i>Mutated Metastatic NSCLC: Insights From Circulating Cell-Free DNA Profiling (Liquid Biopsy Japan Addendum of RELAY Phase 3 Randomized Study).

JTO clinical and research reports·2026
Same author

Frequent RBM10 Comutation and a Mutually Exclusive Relationship With Other TP53 Pathway Aberrations in Early-Stage Non-Small-Cell Lung Cancer with EGFR Mutation.

Clinical lung cancer·2026

Novel genomic technologies enable the discovery of cancer biomarkers for improved diagnosis and treatment. Gene expression profiling aids in predicting treatment response and identifying new therapeutic targets.

Area of Science:

  • Oncology
  • Genomics
  • Biomarker Discovery

Background:

  • Tumor heterogeneity impacts clinical outcomes, necessitating advanced diagnostic and prognostic tools.
  • The integration of novel genomic technologies into clinical trials is expanding.
  • Personalized cancer treatment strategies rely on a deep understanding of tumor biology.

Purpose of the Study:

  • To leverage new genomic technologies for identifying novel cancer biomarkers.
  • To enhance cancer diagnosis, prognosis, and prediction of treatment response.
  • To discover new therapeutic targets and guide the development of innovative anti-cancer agents.

Main Methods:

  • Simultaneous analysis of thousands of genes and their expression profiles using advanced genomic techniques.

Related Experiment Videos

  • Utilizing gene expression profiles to identify biomarkers for pharmacodynamic effects and toxicity.
  • Investigating Epidermal Growth Factor Receptor (EGFR) mutation as a predictive biomarker for targeted therapies.

    • Main Results:

    • Genomic technologies facilitate the discovery of biomarkers for improved diagnosis and treatment prediction.
    • Pharmacodynamic markers, such as EGFR mutations, can predict treatment efficacy earlier than clinical response.
    • Standardization of assay systems and sensitive detection methods are crucial for molecular correlative studies.

    Conclusions:

    • Genomic profiling and biomarker analysis are essential for advancing precision oncology.
    • Targeted therapies, like EGFR inhibitors, show promise when guided by specific biomarkers.
    • Ongoing research focuses on sensitive detection methods for biomarkers in various clinical samples.